Analyst Ratings For Circassia Pharmaceuticals PLC (LON:CIR)
Today, Peel Hunt reiterated its Buy rating on Circassia Pharmaceuticals PLC (LON:CIR).
There are 2 Hold Ratings, 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on Circassia Pharmaceuticals PLC (LON:CIR) is Buy with a consensus target price of GBX 110.25 per share, a potential .
Some recent analyst ratings include
- 12/18/2018-Circassia Pharmaceuticals PLC (LON:CIR) had its Buy rating reiterated by Peel Hunt
- 9/27/2018-Circassia Pharmaceuticals PLC (LON:CIR) had its Buy rating reiterated by Numis Securities with a GBX 140 price target
- 4/25/2017-Circassia Pharmaceuticals PLC (LON:CIR) had its Buy rating reiterated by Stifel Nicolaus with a GBX 150 price target
About Circassia Pharmaceuticals PLC (LON:CIR)
Circassia Pharmaceuticals plc, a specialty biopharmaceutical company, focuses on the development and commercialization of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It markets novel NIOX asthma management products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners internationally. The company's asthma products comprise Fliveo that targets substitution of Flixotide, which has approved in the United Kingdom, as well as developing Seriveo that targets direct substitution of Seretide. It is also developing various novel specialty treatments for COPD, including Spiriva substitute, Novel LABA/LAMA formulation, and novel COPD therapy formulation. In addition, the company' development pipeline includes a range of treatments for allergies, such as cat allergy, grass allergy, house dust mite allergy, and ragweed allergy. It has a collaboration agreement with AstraZeneca to promote Tudorza for COPD treatment, and has the US commercial rights to late-stage COPD product Duaklir. Circassia Pharmaceuticals plc was founded in 2006 and is headquartered in Oxford, the United Kingdom.
Recent Trading Activity for Circassia Pharmaceuticals PLC (LON:CIR)
Shares of Circassia Pharmaceuticals PLC closed the previous trading session at 57,30 −1,70 2,89 % with 22580 shares trading hands.
